Study of HS-20093 for limited-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug called HS-20093 for people with limited-stage small cell lung cancer that has not spread and has already been treated with chemotherapy and radiation. The goal is to see if this drug helps keep the cancer from coming back, compared to just watching and waiting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have limited-stage small cell lung cancer (SCLC) that cannot be removed with surgery, or you choose not to have surgery.
- You have completed chemotherapy and radiation (chemoradiation) and your cancer has not grown during that treatment.
- You are in good enough health to be up and about (ECOG score 0 or 1).
- You are willing to use birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new combination of drugs (HS-20093 plus other treatments) for people with extensive-stage small cell lung cancer whose cancer has not grown after their first round of treatment. The goal is to see if this new approach can keep the cancer from coming back.
This trial tests a new drug called HS-20093 against a standard drug (topotecan) for people with small cell lung cancer that has returned after initial treatment. The goal is to see which drug works better.
This trial tests a new drug, HS-20093, in people with head and neck squamous cell carcinoma or other solid tumors that have worsened after standard treatments. The goal is to see if the drug can help shrink or slow the growth of these cancers.
This study tests a new combination drug called HS-20093 for people with advanced solid tumors. It aims to see if it is safe and works against cancer that hasn't responded to other treatments.
This trial tests an investigational drug called HS-20093 for people with advanced esophageal cancer or other solid tumors that have not responded to prior treatment. The drug targets a protein on cancer cells called B7-H3, and the study aims to see if it can shrink tumors or slow their growth.
This Phase 1 study tests HS-20117 to see if it is safe and how well it works in people with advanced solid tumors. You may qualify if your cancer has progressed after standard treatments (or you can’t tolerate them) and you can provide new or stored tumor tissue for testing.
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.